Guiheen Lawrence P. 4

What Happened

• Lawrence P. Guiheen, a director of ADMA BIOLOGICS, reported awards on Feb 9, 2026: a grant of 10,690 restricted stock units (RSUs) and a derivative award of 17,730 units (total 28,420 units) at $0.00 (compensation awards, not purchases). No cash was paid; these are equity compensation awards that convert to shares only if and when they vest.

Key Details

• Transaction date: 2026-02-09; filing date (Form 4): 2026-02-11 (filed within the standard 2-business-day window).
• Price: $0.00 per unit (award/grant, transaction code A).
• Vesting: The newly granted RSUs vest in two equal installments (six- and 12-month anniversaries) and become fully vested on the one-year anniversary, subject to continued service (see footnote F1). Footnote F2 notes the 10,690 RSUs will fully vest on 2027-02-09 and also references 5,445 RSUs from a 2025 grant that vest 2026-02-19.
• Shares/units reported after transaction: the filing references ownership of 89,385 shares of common stock (which includes 50,990 shares held in an irrevocable trust per F3) plus outstanding RSUs noted above.
• Transaction type: Award/Grant (A). These are not open-market buys or sales.

Context

• RSUs and derivative awards are compensation and do not represent immediately tradable shares; they convert to common stock only upon vesting. This filing reflects routine director compensation rather than a market purchase or sale.